Life Sciences

  • May 21, 2026

    9th Circ. Says Judge Overstepped In Fluoride Risk Case

    A Ninth Circuit panel scrapped a ruling that directed the U.S. Environmental Protection Agency to take action to address potentially unsafe levels of drinking water fluoridation, concluding a California federal judge improperly commandeered the case.

  • May 21, 2026

    NFL Teams Valued At $9B In Stake Sales, And Other Rumors

    Two reported NFL stake sales this past week highlight the continued surge in professional sports valuations, fueled in part by the entry of private equity investors.

  • May 21, 2026

    Insurer Can't Nix Counterclaims In $1.8M Judgment Dispute

    A North Carolina federal judge found that a life sciences company's insurer can't avoid counterclaims brought by a former patent holder asserting that the carrier must cover a $1.77 million judgment entered against the company's executives after they were accused of making misrepresentations about taking the company public.

  • May 21, 2026

    UCB Staves Off Seizure Drug Competition After Bench Trial

    UCB Inc. has persuaded a Delaware federal judge to uphold patents covering its seizure medication Nayzilam, a major win given that generic-drug maker Cipla Ltd. already admitted to infringement.

  • May 21, 2026

    9th Circ. Told To Reject J&J Unit's $442M Antitrust Appeal

    Cardiac catheter refurbisher Innovative Health urged the Ninth Circuit to reject the appeal from Johnson & Johnson's Biosense Webster unit seeking to upend its $442 million antitrust judgment, saying the lower court rightly found that Biosense forced hospitals to avoid refurbished catheters in favor of its own.

  • May 21, 2026

    Vape Sellers Say Pa. E-Cig Law Usurps FDA Authority

    Vape companies are looking to stop a Pennsylvania law that would effectively ban most e-cigarettes, claiming in a federal lawsuit that the statute is unconstitutional, would destroy roughly $2 million of their inventory and targets products that federal regulators say helps smokers quit.

  • May 21, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Virginia's governor vetoed legislation to establish adult-use marijuana sales, keeping the state in cannabis legal limbo; Illinois lawmakers introduced legislation to rein in hemp products, aligning state policy with an upcoming shift in federal law; and Louisiana lawmakers sent a bill to the governor that would allow terminally ill patients to access medical marijuana in healthcare facilities. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • May 21, 2026

    BigLaw Deals Scandal Puts Boston Back On White Collar Map

    A sweeping insider trading case involving information stolen from BigLaw firms shows a return to bread-and-butter white collar enforcement for Boston federal prosecutors and provides a morale lift in an office that has seen shifting priorities and staff turnover since the signature "Varsity Blues" takedown in 2019, veteran prosecutors told Law360.

  • May 21, 2026

    Immunity Bid Can't Stop Discovery In THC Abuse Registry Suit

    There's little chance that the Idaho state health director can ditch litigation by mothers challenging the automatic placement of women on the child abuse registry for prenatal THC use, a federal judge said after taking a "preliminary peek" at the state's pending motion to dismiss.

  • May 21, 2026

    Amgen Wants To Preserve Right To Seek Double Tax Relief

    Drugmaker Amgen wants to preserve its right to seek a refund for tax years 2010 through 2015 if the IRS "persists" in taking a position inconsistent with the agency's own arguments pertaining to those years in its audit of 2016 to 2018, the company told the U.S. Tax Court.

  • May 21, 2026

    Texas Comptroller Tells 5th Circ. To Toss E-Cig Ban Suit

    The acting comptroller for Texas is asking the Fifth Circuit to overturn an order allowing vape companies and a trade association to pursue a suit challenging a state law banning e-cigarette products that use liquids from China and other "adversaries," saying the comptroller is entitled to sovereign immunity.

  • May 21, 2026

    Fed. Circ. Backs Lupin Win In Generic Kidney Drug Case

    The Federal Circuit on Thursday affirmed a Delaware federal judge's ruling that Indian generic-drug maker Lupin's version of the kidney disease drug Jynarque does not infringe two patents held by Japanese rival Otsuka.

  • May 21, 2026

    AmeriHealth Unit, PBM Sued Over Prescription Claim Fees

    Two Philadelphia pharmacies have filed a proposed class action against AmeriHealth Caritas Health Plan and its in-house pharmacy benefits manager, PerformRx LLC, claiming the companies violate Pennsylvania law by not disclosing "transmission fees" at the time a claim is run through the pharmacies' computers, according to a complaint removed to federal court.

  • May 21, 2026

    Zantac Cases To Proceed During Appeal Of Recusal Denial

    The Philadelphia judge overseeing the city's Zantac cancer mass tort will not halt proceedings while Keller Postman LLC appeals his refusal to recuse himself from the litigation on the basis that his wife works at Blank Rome LLP, which represents a pharmaceutical company in one of the 550 cases.

  • May 20, 2026

    Prof. Hired By J&J In 1970s Found Asbestos In Talc, Jury Told

    A former Johnson & Johnson toxicologist could not find evidence his employer turned over a report to the U.S. Food and Drug Administration that "unmistakably" found asbestos in the company's talc, according to a video deposition shown Wednesday to a California jury considering bellwether claims over three women's deadly ovarian cancer.

  • May 20, 2026

    DOJ, Drugmakers Spar After Justices Snub 6 Negotiation Suits

    The U.S. Department of Justice is trying to have it both ways in drug pricing litigation, telling the U.S. Supreme Court not to intervene before additional circuits decide pending challenges and then using this week's nonintervention as ammunition against those challenges, drugmakers are arguing at appeals courts.

  • May 20, 2026

    Minnesota Jury Awards $10.2M In Talc Mesothelioma Trial

    A Minnesota state jury has delivered a $10.2 million verdict to a married couple in their suit against Vi-Jon LLC and the makers of other talc products like Johnson & Johnson and Gold Bond in which they alleged the 45-year-old husband's mesothelioma was caused by exposure to body powder products.

  • May 20, 2026

    2nd Circ. Skeptical Of Bid To Boost Drug Royalty Award

    A Second Circuit panel appeared unsympathetic during oral arguments on Wednesday to Acorda Therapeutics Inc.'s assertion that it should be awarded nearly $66 million beyond the $16.5 million it won in a multiple sclerosis drug dispute, with one judge remarking that the company is "kind of in the soup" because it chose arbitration.

  • May 20, 2026

    1st Circ. Allows Transfer Of RI Youth Care Info To Texas Court

    The First Circuit declined to halt a Texas federal court's order requiring a Rhode Island hospital to hand over records detailing its provision of gender-affirming care to minors, finding a Rhode Island agency failed to demonstrate that doing so would cause children in the state irreparable harm.

  • May 20, 2026

    Refusing Sandoz Parent Dismissal 'Clear Error,' Court Told

    Sandoz's Swiss parent company wants a Pennsylvania federal judge to rethink her decision forcing it to face generic drug price-fixing claims from major employers like General Motors, arguing the court "conflates" Novartis AG with Sandoz AG, which was spun off in 2023.

  • May 20, 2026

    Eli Lilly Loses Bid To Limit Ex-FDA Chief's Take In GLP-1 MDL

    A Pennsylvania federal judge said Eli Lilly & Co. and plaintiffs in multidistrict litigation accusing it of downplaying side effects of weight loss drugs were talking past each other in a dispute over expert testimony, denying Eli Lilly's bid to limit the opinions of the plaintiffs' expert to those disclosed in his report.

  • May 20, 2026

    Tiversa Escapes LabMD's Final Defamation Claims

    A defunct cancer screening lab cannot show that a cybersecurity firm CEO had "actual malice" when he made allegedly defamatory statements about a file of private health info being "exposed," "leaked" and "publicly available" nearly 20 years ago, a federal magistrate ruled in dismissing a long-running lawsuit Tuesday.

  • May 20, 2026

    Eli Lilly Paying Up To $202M In Genetic Medicine Deal

    Eli Lilly and Co. has agreed to acquire privately held Engage Biologics Inc., which is developing a delivery technology for genetic medicines, in a deal worth up to $202 million, Cooley LLP-advised Engage announced Wednesday.

  • May 20, 2026

    Intellia Drops Counterclaims In Gene-Editing Patent Case

    Intellia Therapeutics Inc. has agreed to drop a set of claims it asserted in a Delaware federal suit brought by BlueAllele, which accused it of infringing three gene-editing patents to bring in $100 million in a deal with Regeneron Pharmaceuticals.

  • May 20, 2026

    Squires Institutes 5 Patent Reviews, Rejects 7 Others

    U.S. Patent and Trademark Office Director John Squires on Tuesday granted five requests for review of patents under the America Invents Act while turning down seven other petitions.

Expert Analysis

  • At The Fed. Circ., Means-Plus-Function Is Not Quite Dead

    Author Photo

    Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.

  • E-Discovery Quarterly: Recent Rulings On ESI Control

    Author Photo

    Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

  • 2 Discovery Rulings Break With Heppner On AI Privilege Issue

    Author Photo

    While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.

  • Series

    Isshin-Ryu Karate Makes Me A Better Lawyer

    Author Photo

    My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.

  • Microplastics On Water Contaminant List Could Spur Claims

    Author Photo

    The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.

  • USPTO's AI Search Pilot May Reshape Patent Filing Strategy

    Author Photo

    The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.

  • Peptide Policy Is Shifting Toward Sanctioned Compounding

    Author Photo

    The policy landscape for peptides is undergoing a significant shift under the Trump administration, moving toward a complex system of verified compounding and complementary enforcement that will likely bring peptides firmly back into the sphere of legitimate consumer products, say attorneys at Sheppard.

  • Keys To Building Defensible Psychedelic Therapy Programs

    Author Photo

    Given the rapidly evolving legal environment for psychedelic therapies and heightened liability and compliance risks facing providers, meticulous documentation, robust risk management protocols, and proactive engagement with professional organizations and insurers are essential strategies, say Kimberly Chew at Husch Blackwell and L. Alison McInnes at Mindful Health Solutions.

  • Opinion

    State Bars Need To Get Specific About AI Confidentiality

    Author Photo

    Lawyers need to put actual client information into artificial intelligence tools to get their full value, but they cannot confidently do so until state bars offer clear, formal authority on which plan tiers of the three most popular generative AI tools are safe to use when sharing specific client details, says attorney Nick Berk.

  • Series

    Alpine Skiing Makes Me A Better Lawyer

    Author Photo

    Skiing has shaped habits I rely on daily as an attorney — focus, resilience and the ability to remain steady when circumstances shift rapidly — and influences the way I approach legal strategy, client counseling and teamwork, says Isaku Begert at Marshall Gerstein.

  • FDA Guidance May Move Goalposts For Form 483 Responses

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration provides formal insight on how drug manufacturers are expected to respond to Form 483s, raising some concerns about the agency's timelines and expectations, say attorneys at Cooley.

  • 2 Strands Of Patent Law In High Court's 'Skinny Label' Case

    Author Photo

    Amarin v. Hikma, which is set for oral argument in the U.S. Supreme Court this month, highlights the distinction between two different strands of intellectual property law — analogizing a patent to either a property deed or a home, says Jonas McDavit at Spencer West.

  • Why MDLs Slow Down — And How To Speed Them Up

    Author Photo

    Multidistrict litigation has become central to mass tort practice, but as MDLs grow in size and complexity, so do delays and costs — so tools like the new federal rule governing MDLs, targeted use of special masters and strategically deployed Lone Pine orders are more essential than ever, say attorneys at Ice Miller.

  • A Check-Up On HHS' Push To Implement AI Infrastructure

    Author Photo

    The U.S. Department of Health and Human Services has made some headway in its efforts to implement artificial intelligence across its agencies, but will have to overcome a number of near-term tests in order to be successful, says Theodore Thompson at Stinson.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.